Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015

Future Oncology

Volumn 1, Issue 6, 2005, Pages 763-766

  Ries, Stefan J ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

cancer therapy; dl1520; heat shock; oncolytic virus; ONYX 015; virotherapy

Indexed keywords

EID: 33750059545     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.763     Document Type: Note

References (15)

1. OShea C, Soria C, Bagus B, McCormick F: Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic therapy. Cancer Cell 8, 61-74 (2005).
2. Ries S, Brandts C: Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today 9(17), 759-768 (2004).
3. Ries S, Korn M: ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 86, 5-11 (2002).
4. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121 (1987).
5. Dobner T, Horikoshi N, Rubenwolf S, Shenk T: Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272(5267), 1470-1473 (1996).
6. Bischoff JR, Kirn DH, Williams A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996).
7. Khuri FR, Nemunaitis J, Ganly I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879-885 (2000).
8. Goodrum FD, Ornelles DA: p53 status does not determine outcome of E1B 55- kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-9490 (1999).
9. Harada JN, Berk AJ: p53-independent and -dependent requirements for E1B-55K in adenovirus Type 5 replication. J. Virol. 73, 7474-7488 (1999).
10. Babiss LE, Ginsberg HS, Darnell JE: Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5, 2552-2558 (1985).
11. Leppard KN, Shenk T: The adenovirus 55kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J. 8, 2329-2336 (1989).
12. Pilder S, Moore M, Logan J, Shenk T: The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell. Biol. 6, 470-476 (1986).
13. OShea CC, Johnson L, Bagus B et al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623 (2004).
14. Thorne SH, Brooks G, Lee YL et al.: Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer. J. Virol. 79, 581-591 (2005).
15. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nature 2(7), 566-580 (2003).